Walgreens Boots Alliance (WBA), one of the largest retail pharmacies in the U.S., has agreed to pay $269 million to the federal and state governments to settle allegations of fraudulently overdispensing insulin pens and violating the False Claims Act for billing Medicaid at rates higher than its usual rates for certain prescription drugs.

In the first instance, the retailer did not always adhere to the dosage that was prescribed by physicians for insulin pens and, instead, dispensed boxes containing five pens, regardless of patient needs. As a result, Medicare and Medicaid beneficiaries routinely received more insulin than prescribed and Walgreens billed Medicaid for the additional doses, according to court documents.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ed,
    I don’t get it Ed !! Please tell me why there are one set of rules for big corporate
    chain pharmacies and different rules for independent pharmacies ? Is it because they own the PBM’s that are fleecing this country too? There isn’t one congressman or senator that sees this and wants to do the right thing for America ? Can you please show this article and my response to Donald !!!!!!!!!!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy